SpectrumX’s SPC-069 Respiratory Treatment Shows Unprecedented Efficacy against Multiple Coronavirus Variants
- Wall Street closes at record but Facebook weighs
- Alphabet (GOOGL) Revenue Surges 41% in Q3, Stock Dips
- Microsoft (MSFT) Stock Gains on Q1 Beat as Cloud Revenue Surges 36%
- Robinhood (HOOD) Stock Dips 8% on Worse Than Expected Q3 Results as MAUs Drop, Equities Dip 27%, and Crypto Rises 860%
- Intel (INTC) Sees Insider Buys from CEO Gelsinger and 4 Other Insiders
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Independent study at Medical University Innsbruck reports 100% neutralisation of Wuhan, Alpha and Delta strains within one minute
LONDON--(BUSINESS WIRE)-- SpectrumX, a UK-based healthcare and pharmaceutical company, announced today its SPC-069 respiratory treatment has shown 100% efficacy in neutralising the most common variants of SARS-CoV-2 (Coronavirus) in an independent in vitro study.
Conducted by Medical University Innsbruck, Institute of Hygiene and Medical Microbiology, and performed under the direction of Prof. Dr. Wilfried Posch, it investigated the neutralising capacity of SpectrumX’s SPC-069 treatment for the SARS-CoV-2 Wildtype (Wuhan), SARS-CoV-2 Alpha (B.1.1.7) and SARS-CoV-2 Delta (B.1.617.2) strains at various times of exposure. In vitro neutralisation of the virus treated with SPC-069 was 100% in all cases at exposure levels of one minute, five minutes, 10 minutes, 30 minutes and 60 minutes.
The tests also looked at toxicity of the treatment on human cells, and showed a minimal and harmless reduction of cells, with the report lauding the antiviral and non-cytotoxic effects of undiluted SPC-069.
SPC-069 is a patent-protectable nebulizer treatment which deploys HOCL (hypochlorous acid), the human body’s defence against pathogens. The substance is produced by white blood cells, and thus is noncarcinogenic and safe for skin, eyes and lungs. The product will shortly begin trials ahead of emergency use applications with both the European Medicines Agency (EMA) and Medicines & Healthcare products Regulatory Agency (MHRA) as a treatment for COVID-19 as well as other respiratory ailments such as influenza, common cold, bronchitis and pneumonia.
Damien Hancox, CEO & Co-Founder of SpectrumX, said: “This study shows the most promising results thus far in our battle against COVID-19 and other respiratory illnesses. Our aim is the delivery of the safest and most effective treatment for all variants of COVID-19, which can dramatically reduce hospitalisation and death amongst patients. This data takes us one step closer to fully deploying the treatment across the UK and Europe and hopefully setting us back on a path to normality.”
Prof. Dr. Wilfried Posch, Medical University Innsbruck’s Institute of Hygiene and Medical Microbiology, said: “The combination of 100% viral neutralisation and extremely low levels of cytotoxicity to human cells within just one minute is very promising. Our in vitro data clearly demonstrate that SPC-069 is both effective and carries minimal toxicity to human cells, and we believe it is ready for patient trials.”
- ENDS -
SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market a ground-breaking respiratory therapy (SPC-069) and the roll out of the most powerful hand sanitiser in the world to the NHS and other healthcare clients. Both products utilise unique patent pending HOCL formulations. HOCL is naturally occurring in human’s white blood cells and is a key contributor to mankind’s evolution and protection over millions of years. It is human safe whilst also being the most effective disinfectant known to mankind.
Luther Pendragon (on behalf of SpectrumX)
+44 (0)20 7618 9100
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Financial Institution Credit Card Programs Get a Competitive Boost with Fully Managed Option from Fiserv
- Bandwidth Announces Preliminary Third Quarter 2021 Revenue Results Exceeding Guidance and Estimated Full Year Revenue Impact of DDoS Attack
- Spirit AeroSystems Announces Quarterly Cash Dividend
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!